INTERNATIONAL MULTI DISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT
eISSN 2394-6334 Impact factor: 8.854 Volume 13, issue 04 (2026)

NEUROLOGICAL DISORDERS ACCOMPANIED BY COGNITIVE IMPAIRMENTS AND THE RELEVANCE OF OPTIMIZING THEIR TREATMENT

Sokhib Rashidov Zamon o'g'li
Davronbek A'zamov Salim o'g'li
Zukhriddin O‘rishboev Alisher o‘g‘li
Department of the pharmacology of the Tashkent state medical university

Abstract. Cognitive impairments are often linked to Parkinson's disease (PD), a neurodegenerative ailment. These may result directly from the underlying illness or may be brought on by outside variables in vulnerable people who have Parkinson's disease or other risk factors. The cognitive disorders include delirium, cognitive side effects of PD treatment, cognitive non-motor fluctuations, PD-associated psychosis, and PD-associated cognitive impairment (PD-CI). Since delirium frequently results from an underlying illness that may be severe and call for specialized care, an accurate diagnosis is essential. A general deterioration in memory and other cognitive abilities that is severe enough to impair a person's capacity to carry out daily tasks is referred to as dementia. It is characterized by a steady and progressive decline in cognitive function. Memory loss and a partial or substantial lack of understanding of their deficiencies are common in affected patients. The assessment and treatment of dementia are reviewed in this activity, which also emphasizes the interprofessional team's involvement in providing care for patients with this illness. It also discusses pathogenesis, risk factors, and difficulties in identifying and treating this range of cognitive illnesses. However, it is believed that delirium and Parkinson's disease (PD) have comparable clinical symptoms due to shared molecular pathways. Furthermore, delirium and PD-CI interact in both directions, leading to frequent concurrent processes that make identification even more challenging. Currently, there is no trustworthy biomarker for delirium, and clinical criteria are the main basis for diagnosis. However, there is no specific validation for PD in the screening techniques that have been validated for identifying delirium in the general population. Our review identifies current gaps in the research and discusses the difficulties in diagnosing these cognitive impairments.

Keywords. Alzheimer's disease, Psychiatry for the elderly, Mental Illness, The study of neuropsychology, Parkinson's illness, Mental Illness, Parkinson's Disease Non-Motor Symptoms, Treatment Strategies.

Introduction. Neurological Disorders (ND) heavily rely on medical imaging methods, especially Magnetic Resonance Imaging (MRI), for monitoring and diagnosis. Alzheimer's disease (AD), Parkinson's disease (PD), and brain tumors (BT) are common findings in neurodegenerative diseases (ND), although they can be difficult to identify with conventional diagnostic techniques. Healthcare professionals can identify conditions including muscle atrophy, lesions, and other diseases thanks to the full visibility of brain structures made possible by MRI's high-resolution images, a non-invasive imaging modality. To identify small differences that might be signs of early-stage ND, a certain degree of specificity is necessary. These variations may go undetected by traditional imaging methods like CT scans or X-rays. By producing 2D and 3D images of the brain's cortex, magnetic resonance imaging (MRI) may precisely examine the structure and function of the brain, aiding in the diagnosis and tracking of illness progression. Furthermore, discrete cell features are demonstrated by T1-weighted and T2-weighted scans, two extremely advanced MRI kinds that increase the size to detect a standard range of ND [1-6]. Because of this, MRI has become essential for the early diagnosis and treatment of ND, providing important data that guides treatment decisions and improves patient outcomes. One of

the most prevalent types of neurological illnesses, especially in older individuals, is cognitive impairments (CIs). The cause and severity of anomalies influence the therapy approach for CI. Adequate treatment of pre-existing cardiovascular diseases, avoidance of stroke, balanced nutrition, moderate physical and intellectual exercise, and combating obesity and low activity are fundamental strategies to prevent the advancement of CI and dementia. The aforementioned actions lower the incidence of dementia, even in those who are genetically susceptible, according to findings from several studies. Vasoactive, neurometabolic, and noradrenergic drugs are typically used in pharmacotherapy for mild to moderate CIs. Even though MRI is a great tool for detecting the structure of the brain, there are still a lot of issues with traditional diagnostic techniques that call for human interpretation of MRI pictures. The need for highly skilled radiation oncologists to evaluate MRI scans is one of the main disadvantages [7-12]. This need for knowledge enhances and affects the diagnosis process because there may not always be a large number of highly skilled specialists available to work, especially in areas of medical treatment that are underprivileged or distant. Additionally, when human interpretation is involved, diagnosis is likely to be inaccurate because different radiologists may reach different conclusions from exactly the same MRI data. The accuracy of the condition identification may be adversely affected in early-stage ND instances where minor changes have emerged. Physically identifying these concealed structural alterations is sometimes challenging and easily overlooked, despite the need of early discovery for successful therapy. Radiologists utilize precise, identical, and robotic diagnostic equipment to assist doctors in early detection and diagnosis of ND in order to overcome these limitations and improve outcomes for patients and healthcare delivery. The need for automated and precise ND diagnostics has increased because early detection is essential for improving patient care. Due to the fact that early treatment for conditions like AD or brain tumors can significantly reduce the disease's spread and improve quality of life, conventional diagnostic techniques usually fail to identify these problems in their early stages [13-16]. Automated diagnostic systems offer precise results with little room for error when used in place of human analysis. In particular, machine learning (ML) models made significant strides in this area by using large data sets to learn how to identify intricate structures in MRI pictures that people might have found challenging. Furthermore, rather than attaining a balanced integration of all aspects, these models often stress one spatial or temporal FE. Together, these constraints lower diagnostic accuracy, especially for early-stage detection when the most useful diagnostic information is found in small alterations across spatial and temporal dimensions. A unified approach utilizing CNN for spatial characteristics, STGCN for temporal tracking, and self-AM based on used transformers is required to increase the accuracy of early diagnosis and ND detection. Neurological conditions like multiple sclerosis, Parkinson's disease, and Alzheimer's disease can cause cognitive loss and disability [17-23]. The progressive deterioration of neurons and neural networks in different parts of the brain causes several illnesses, which impair cognitive function. Conventional therapy approaches frequently fail to limit cognitive decline, despite breakthroughs in our knowledge of these illnesses. Comorbid conditions like anxiety, depression, and sleep difficulties frequently accompany these diseases and can significantly affect cognitive function. Thus, it is crucial to create tailored treatments and diagnostic instruments for cognitive decline and impairment. The most frequent types of dementia (Alzheimer's disease, Lewy body dementia, vascular, and mixed dementia), hepatic colic, and severe CIs are all indications for the use of memantine and/or acetylcholinergic medications. Long-term usage of memantine and/or acetylcholinergic drugs reduces dementia's behavioral and cognitive symptoms, increases patients' sense of independence, and extends their active lives [24-31].

The main purpose of the presented manuscript is a brief commentary on the results of reputable scientific papers on neurological disorders accompanied by cognitive impairments and the relevance of optimizing their treatment.

Investigating Biomarkers in the Diagnosis of Neurological Disorders. ALS patients had higher levels of plasma glial fibrillary acidic protein than controls, according to a carefully planned study by Mastrangelo et al. Concurrent Alzheimer's disease pathology was the main cause of this rise, indicating its potential as a trustworthy biomarker for cognitive impairment in ALS. It seems clear that neurological disorders like ALS and Alzheimer's disease may be more closely related than previously believed as we learn more about the molecular causes of cognitive impairment. By expanding our knowledge of the disease mechanisms and providing new therapeutic targets, this work has the potential to transform therapy paradigms and give people suffering from these crippling illnesses hope. CSF protein analyses and neuropsychometric tests are frequently used in clinical settings to evaluate dementia patients and are essential to the diagnosis of the illness [5-11]. Although more current biomarkers are being studied, the most widely utilized CSF diagnostic biomarkers for Alzheimer's disease are β-amyloid, total tau protein, and phospho-tau protein. This special issue includes two more pieces that go into further detail on this subject. While one looks at diagnostic biomarkers for evaluating cognitive impairment in individuals with the behavioral variety of frontotemporal dementia, the other analyzes the current level of our knowledge regarding CSF biomarkers in Alzheimer's disease diagnosis [14-20].

Advances in Diagnosis and Treatment Technology. Cutting-edge technological developments have the potential to completely change the field of cognitive impairment diagnosis and treatment approaches. These developments usher in a new age in neurological care, from advanced neuroimaging methods that provide previously unattainable views of the structure and function of the brain to the identification of biomarkers that enable early detection and intervention. The complexity of cognitive impairment across neurological illnesses is highlighted by the shift to personalized medicine, where treatments are customized to each patient's own genetic composition and disease manifestation. It pushes us to reconsider our strategies and promote therapies that treat the patient as a whole rather than simply the disease [6-13].

A case study of the crucial tremor-cognition nexus. Within this larger investigation into the cognitive landscape of neurological illnesses, examining the relationship between essential tremor (ET) and cognitive impairment is a classic case study. ET has recently been examined through the perspective of cognitive science, indicating considerable parallels with cognitive abnormalities. Traditionally, ET was thought to be largely a motor system problem distinguished by its tremulous manifestations. The oversimplified classification of ET as only a motor illness has started to be challenged by recent research, which sheds light on how ET interacts with cognitive processes. According to studies, people with ET are more likely to experience cognitive abnormalities, such as executive dysfunction, memory problems, and issues with attention and processing speed [21-25]. It is crucial to assess ET holistically, taking into account both motor and cognitive symptoms, as these cognitive difficulties can have a significant impact on day-to-day functioning and health-related quality of life. Rethinking diagnostic standards and treatment approaches is prompted by the discovery that ET may have a substantial cognitive component. It recommends that academics and physicians take a more all-encompassing approach to comprehending and treating ET, incorporating cognitive assessment and therapies as essential elements of treatment. Furthermore, this new understanding of ET as a neurodegenerative condition with both motor and cognitive symptoms is consistent with contemporary neuroscience advances that highlight the interdependence of brain systems. These results make the ET–cognition connection a crucial topic for further study. In order to create

tailored therapeutic options that address the entire spectrum of ET, it is imperative to investigate the underlying mechanisms that relate ET to cognitive impairment. Additionally, comprehending the connection between ET and cognitive processes may offer important insights into the more general rules controlling the interplay between motor disorders and cognition, which may have consequences for a number of neurological illnesses [27-33].

Patient-Centered Care: A Change in Perspective. The move to patient-centered care is a fundamental reorientation of our treatment and care philosophies amid scientific and technical developments. Understanding the significant impacts that cognitive impairment has on people's lives calls for strategies that go beyond treating the basic components of illnesses. Rather, there is a growing need for methods that improve patients' general well-being while taking into account their physical, emotional, social, and psychological requirements [31-35].

Future Prospects and Difficulties. As we stand on the brink of discoveries, the road ahead is full of potential and challenges. The potential to decipher the intricacies of cognitive impairment in neurological illnesses depends on our capacity to carry out long-term research, incorporate state-of-the-art technologies, and promote interdisciplinary cooperation. This journey is made possible by the research described in the Special Issue, which provides insights and poses questions to spur further investigation. The cognitive landscape of neurological illnesses requires constant learning and adaptation. We hope that the contributions to the International Journal of Molecular Sciences Special Issue on "Cognitive Impairment in Neurological Diseases" will provide insightful information about how to assess cognitive impairments in a range of neurological illnesses. We also hope that it will spark creative thinking and new research directions among our readers and the scientific community at large. In order to overcome the obstacles and seize the opportunities in our pursuit of reducing cognitive impairment within the broad field of neurological sciences, cooperation, creativity, and patient-centered care will be essential [33-40].

Discussion. The second most prevalent neurodegenerative disease, Parkinson disease (PD), affects more than 1% of people over 65 and is expected to double in prevalence by 2030. Cognitive impairment is one of the many non-motor symptoms of Parkinson's disease (PD) that can arise at any stage of the disease, in addition to the characteristic motor symptoms. Although it can happen quickly in certain situations, cognitive decline is often gradual and subtle. The emphasis has recently shifted to the early cognitive alterations, where executive and visuospatial abnormalities are common and can be accompanied by memory impairment, raising the likelihood of dementia developing early. Diagnosis may be straightforward in the early stages of the disease, but as the disease progresses and baseline cognitive symptoms become more evident, this task becomes more challenging. There is a bidirectional relationship between delirium and PD-CI, where delirium is a risk factor for PD-CI and vice versa. Hence, a higher percentage of PD patients experiencing delirium will have CI, further complicating the diagnostic process. Additionally, there is a clinical overlap and synergy between delirium and PD. They both share common symptoms, making it challenging to differentiate between delirium and other cognitive and behavioral disorders in PD [6-13]. Visual hallucinations, advanced age, biomarker alterations such cortical shrinkage, Alzheimer-type alterations on functional imaging and in cerebrospinal fluid, and slowness and frequency variation on EEG are additional risk factors for early dementia progression. However, little is known about the mechanisms behind cognitive deterioration in Parkinson's disease. Alzheimer-type diseases and Lewy body cortical involvement are important characteristics, however there are probably several processes at play. The only high-level evidence-based treatment now available is cholinesterase inhibition, however additional pharmacological and non-pharmacological approaches are being investigated. Finding biomarkers to better predict cognitive decline and identify people at high risk for early

and rapid cognitive impairment are challenges, as is the discovery of disease-modifying treatments. FDA-approved medications to improve cognitive function include cholinesterase inhibitors and memantine. Cholinesterase inhibitors include donepezil, galantamine, and rivastigmine. Cholinesterase inhibitors prevent the breakdown of acetylcholine and aim to slow or delay the worsening of symptoms [23-31]. Memantine is an NMDA antagonist and decreases the activity of glutamine. Donepezil is approved for all stages of Alzheimer disease, rivastigmine is approved for all stages of Alzheimer disease in its patch form, and mild to moderate stages with oral formulations. Galantamine is approved for mild to moderate stages and memantine for moderate to severe stages Behavioral symptoms include irritability, anxiety, and depression. Antidepressants and sometimes antipsychotics can help with these symptoms. In addition, non-drug approaches like supportive care, memory training, physical exercise programs, and mental and social stimulation must be employed in symptom control. Patients and their families should be counseled about the disease and its consequences. They should be provided with all the necessary information about what to expect and how to react. Patients and their families should also be encouraged to seek social service consultations and to register with support groups and societies. Coaching caregivers on skills such as redirection and reassurance as opposed to repeated correction of patients confused due to dementia can avoid or de-escalate possible behavioral symptoms. Driving restrictions may have to be imposed [32-39].

Conclusion. PD-CI, delirium, cognitive side effects of PD drugs, cognitive NMF, and PD-associated psychosis are all considered cognitive abnormalities in Parkinson's disease (PD). These can be broadly divided into those that are largely brought about by the illness and those that need the involvement of other outside variables. Differentiating delirium from other cognitive or behavioral abnormalities in Parkinson's disease (PD) is crucial because delirium needs a unique etiological treatment, whilst the latter can only be treated symptomatically. As of right now, there is no accepted gold standard for detecting delirium; instead, clinical assessment is used. Furthermore, no clinical scale that is utilized in the general population has been proven to be valid in people with Parkinson's disease.

In the end, it is challenging to determine exactly when PD-CI ends and delirium begins because there is no obvious distinction between the labels used for both conditions. The pathophysiology of delirium and Parkinson's disease (PD) involves similar pathways, indicating that they might belong to a spectrum. Similar ideas have already been used in psychiatry, where individual aspects are included into a biopsychosocial model and the distinction between endogenous and reactive depression has been dropped [90]. Every PD patient with a cognitive problem has a partial delirium component, which should be suspected. The practical outcome for daily clinical practice would be to continuously use the suggested diagnostic and general delirium measures to reduce this component as much as feasible.

In conclusion, it is clinically crucial to recognize delirium as the sole type of PD-CI that may be completely reversible when properly handled, going beyond a suitable nomenclature by which we attempt to classify a spectrum of cognitive impairments in PD. Future studies should concentrate on finding particular delirium biomarkers that apply to Parkinson's disease (PD) and establishing clinical scales that non-specialist doctors can use in clinical practice.

References.

1. Bonnechère B, Amin N, van Duijn C. What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review. Int J Mol Sci. 2022 Nov 8;23(22):13665. doi: 10.3390/ijms232213665.
2. Benito-León J, Papaliagkas V. Cognitive Impairment in Neurological Diseases. Int J Mol Sci. 2024 Apr 18;25(8):4435. doi: 10.3390/ijms25084435.

3. Aarsland, D., Batzu, L., Halliday, G.M. et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7, 47 (2021). https://doi.org/10.1038/s41572-021-00280-3
4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
5. Chojnacki, C.; Konrad, P.; Błońska, A.; Medrek-Socha, M.; Przybylowska-Sygut, K.; Chojnacki, J.; Poplawski, T. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth. Nutrients 2022, 14, 3217.
6. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
7. Socała K., Doboszewska U., Szopa A., Serefko A., Włodarczyk M., Zielińska A., Poleszak E., Fichna J., Wlaź P. The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders. Pharmacol. Res. 2021;172:105840. doi: 10.1016/j.phrs.2021.105840.
8. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
9. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
10. Góralczyk-Bińkowska, A.; Szmajda-Krygier, D.; Kozłowska, E. The Microbiota–Gut–Brain Axis in Psychiatric Disorders. Int. J. Mol. Sci. 2022, 23, 11245.
11. Heiss C.N., Olofsson L.E. The Role of the Gut Microbiota in Development, Function and Disorders of the Central Nervous System and the Enteric Nervous System. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.
12. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
13. Angst D., Gessier F., Janser P., Vulpetti A., Wälchli R., Beerli C., et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's Tyrosine Kinase. J. Med. Chem. 2020;63(10):5102–5118. doi: 10.1021/acs.jmedchem.9b01916.
14. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06

15. Guerra E., Garcia-Sanchez Y., Jornet-Gibert M., Nuñez J., Balaguer-Castro M., Madden K. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2022;54((Suppl. S3)):S26–S29. doi: 10.1016/j.injury.2022.01.047.
16. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
17. Asahina Y., Wurtz N.R., Arakawa K., Carson N., Fujii K., Fukuchi K., et al. Discovery of BMS-986235/LAR-1219: a potent formyl peptide receptor 2 (FPR2) selective agonist for the prevention of heart failure. J. Med. Chem. 2020;63(17):9003–9019. doi: 10.1021/acs.jmedchem.9b02101.
18. Sanoev Z.I., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Hamroyev T.T. Study Of The General Pharmacological Properties Of A New Antiarrhythmic N-Deacetyllappaconitine With Oral Administration. The American Journal of Medical Sciences and Pharmaceutical Research, 3(03), 60-64. https://doi.org/10.37547/TAJMSPR/Volume03Issue03-08
19. Patton E.E., Zon L.I., Langenau D.M. Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat. Rev. Drug Discov. 2021;20:611–628. doi: 10.1038/s41573-021-00210-8.
20. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
21. Stokes, J.M.; Yang, K.; Swanson, K.; Jin, W.; Cubillos-Ruiz, A.; Donghia, N.M.; MacNair, C.R.; French, S.; Carfrae, L.A.; Bloom-Ackermann, Z. A deep learning approach to antibiotic discovery. Cell 2020, 180, 688–702.e613.
22. Sanoev, Z.I., Djaxangirov, F.N., Sadikov, A.Z., Sagdullaev, S.S. Hamroyev T.T. Antiarrhythmic activity of N-deacetyllappaconitine when administered orally. Annals of the Romanian Society for Cell Biology,2021,25(2), 2339–2346. https://doi.org/10.37547/tajas/Volume03Issue03-06
23. Thafar, M.A.; Alshahrani, M.; Albaradei, S.; Gojobori, T.; Essack, M.; Gao, X. Affinity2Vec: Drug-target binding affinity prediction through representation learning, graph mining, and machine learning. Sci. Rep. 2022, 12, 4751.
24. Sokhib Rashidov Zamon o‘g‘li, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
25. Frileux, S.; Boltri, M.; Doré, J.; Leboyer, M.; Roux, P. Cognition and Gut Microbiota in Schizophrenia Spectrum and Mood Disorders: A Systematic Review. Neurosci. Biobehav. Rev. 2024, 162, 105722.
26. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434

27. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
28. Kong Y.K., Song K.-S., Jung M.E., Kang M., Kim H.J., Kim M.J. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 2022;56 doi: 10.1016/j.bmcl.2021.128466.
29. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
30. Sokhib Rashidov Zamon o‘g‘li, Nilufar Ergasheva Ag’zamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
31. Günther J., Hillig R.C., Zimmermann K., Kaulfuss S., Lemos C., Nguyen D., et al. BAY-069, a Novel (Trifluoromethyl) pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe. J. Med. Chem. 2022;65(21):14366–14390. doi: 10.1021/acs.jmedchem.2c00441.
32. Sokhib Rashidov Zamon o‘g‘li, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Po‘latjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
33. Rosa J.G.S., Lima C., Lopes-Ferreira M. Zebrafish larvae behavior models as a tool for drug screenings and pre-clinical trials: A review. Int. J. Mol. Sci. 2022;23:6647. doi: 10.3390/ijms23126647.
34. Sokhib Rashidov Zamon o‘g‘li, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
35. Sokhib Rashidov Zamon o‘g‘li, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
36. Cockerill G.S., Angell R.M., Bedernjak A., Chuckowree I., Fraser I., Gascon-Simorte J., et al. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. J. Med. Chem. 2021;64(7):3658–3676. doi: 10.1021/acs.jmedchem.0c01882.
37. Sokhib Rashidov Zamon o‘g‘li, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qo‘shbekova

Ro‘zimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857

38. Daniels, C., Rodríguez-Antigüedad, J., Jentschke, E. et al. Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium. Neurol. Res. Pract. 6, 14 (2024). https://doi.org/10.1186/s42466-024-00309-4
39. Emmady PD, Schoo C, Tadi P. Major Neurocognitive Disorder (Dementia) [Updated 2022 Nov 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557444/
40. Vakhnina NV. Current therapy for cognitive impairments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(4):63-69. (In Russ.) https://doi.org/10.14412/2074-2711-2011-349